Share This Page
Drug Price Trends for TRAMADOL HCL ER
✉ Email this page to a colleague

Average Pharmacy Cost for TRAMADOL HCL ER
Drug Name | NDC | Price/Unit ($) | Unit | Date |
---|---|---|---|---|
TRAMADOL HCL ER 200 MG TABLET | 68180-0698-06 | 1.60553 | EACH | 2025-01-22 |
TRAMADOL HCL ER 100 MG TABLET | 47335-0859-83 | 0.93946 | EACH | 2025-01-22 |
TRAMADOL HCL ER 100 MG TABLET | 68180-0697-06 | 0.93946 | EACH | 2025-01-22 |
TRAMADOL HCL ER 300 MG TABLET | 47335-0861-83 | 2.26832 | EACH | 2025-01-22 |
TRAMADOL HCL ER 100 MG CAPSULE | 13811-0689-30 | 7.66255 | EACH | 2025-01-22 |
TRAMADOL HCL ER 200 MG TABLET | 47335-0860-83 | 1.60553 | EACH | 2025-01-22 |
TRAMADOL HCL ER 300 MG TABLET | 68180-0699-06 | 2.26832 | EACH | 2025-01-22 |
>Drug Name | >NDC | >Price/Unit ($) | >Unit | >Date |
Tramadol HCL ER: Market Analysis and Price Projections
Market Overview
Tramadol HCL ER, a extended-release formulation of the opioid analgesic tramadol, is a crucial component in the management of moderate to moderately severe pain in adults. Here’s a comprehensive look at the market analysis and price projections for this drug.
Global Market Size and Growth
The global tramadol market, which includes tramadol HCL ER, was valued at USD 4.24 billion in 2023 and is expected to grow at a Compound Annual Growth Rate (CAGR) of 6.86% from 2024 to 2030, reaching approximately USD 6.75 billion by 2030[1].
Another report indicates that the tramadol drug market was valued at USD 4.5 billion in 2022 and is projected to reach USD 8.6 billion by 2032, growing at a CAGR of 6.8% from 2023 to 2032[3].
Drivers of Market Growth
The growth of the tramadol HCL ER market is driven by several key factors:
- Increasing Prevalence of Chronic Pain: Chronic pain conditions such as arthritis, neuropathy, and fibromyalgia are on the rise globally. For instance, at least 10% of the world’s population is affected by chronic pain, with 1 in every 5 adults suffering from some form of pain[3].
- Aging Population: The increase in the geriatric population, which is more prone to chronic pain and lower back pain requiring surgical and therapeutic interventions, is also boosting the market[3].
- Advancements in Drug Formulations: The introduction of long-acting formulations and combination therapies involving tramadol HCL ER is enhancing market accessibility and demand[4].
- Regulatory Approvals and Government Initiatives: Favourable regulatory approvals and government initiatives, particularly in regions like North America, are driving the market forward[3].
Regional Market Analysis
North America
North America holds the largest share of the tramadol market, with a significant prevalence of pain conditions. According to the Centers for Disease Control and Prevention (CDC), nearly 20.9% of U.S. adults experienced chronic pain, and 6.9% experienced high-impact chronic pain. This region is expected to show considerable growth due to high healthcare expenditure, patient-focused care, and the availability of specialized medical centers[3].
Asia Pacific
The Asia Pacific region is the fastest-growing market for tramadol HCL ER. This growth is attributed to the rising healthcare infrastructure and an increasing demand for pain management solutions in countries like China and India[1].
Europe and Other Regions
Europe and other emerging markets such as Latin America and the Middle East & Africa also show significant growth potential. These regions are driven by increasing healthcare expenditure and a growing need for effective pain management solutions[4].
Competitive Landscape
The tramadol HCL ER market is competitive, with several key players:
- Pfizer Inc.
- J&J Innovative Medicine
- Teva Pharmaceuticals
- GSK plc
- Cipla[1]
- Hainan Huluwa Pharmaceutical Group
- Chengdu Tiantaishan Pharmaceutical
- Ruiyang Pharmaceutical[4]
These companies are involved in the development of new formulations, partnerships with healthcare providers, and expansion into emerging markets.
Price Projections and Cost Analysis
Cash Prices
Without insurance, the cost for tramadol HCL ER can be substantial:
- A supply of 10 tablets of 200 mg/24 hours extended-release tramadol can cost around $107[2].
- A 30-tablet supply of 100 mg extended-release tramadol can cost approximately $150[5].
Generic and Discount Options
Generic versions of tramadol HCL ER are available, which can significantly reduce costs:
- A 30-tablet supply of generic tramadol HCL ER can cost around $140.65[2].
- Using discount cards or programs, such as the SingleCare savings card, can lower the price to as low as $5 for a 30-tablet supply[5].
Distribution Channels and Segments
The market is segmented by dosage form, route of administration, distribution channel, and region. The hospital segment is expected to dominate the market due to the high volume of surgical procedures and chronic pain treatments performed in hospitals[4].
Challenges and Restraints
Despite the growth potential, the tramadol HCL ER market faces several challenges:
- Potential Side Effects: Tramadol, like other opioids, has potential side effects and risks of addiction, which can impact market growth.
- Regulatory Concerns: Strict regulations and monitoring of opioid use can also act as restraints[4].
Key Takeaways
- The global tramadol market, including tramadol HCL ER, is expected to grow significantly due to increasing chronic pain prevalence and advancements in drug formulations.
- North America and the Asia Pacific are key regions driving market growth.
- The market is competitive with major players focusing on new formulations and partnerships.
- Generic and discount options are available to reduce costs for patients.
- Regulatory concerns and potential side effects are significant challenges.
FAQs
What is the projected market size of the tramadol HCL ER market by 2030?
The global tramadol market, which includes tramadol HCL ER, is expected to reach approximately USD 6.75 billion by 2030, growing at a CAGR of 6.86% from 2024 to 2030[1].
What are the main drivers of the tramadol HCL ER market growth?
The main drivers include the increasing prevalence of chronic pain conditions, advancements in drug formulations, and favourable regulatory approvals and government initiatives[3].
Which regions are expected to dominate the tramadol HCL ER market?
North America currently holds the largest share, while the Asia Pacific region is the fastest-growing market for tramadol HCL ER[1][3].
How much does tramadol HCL ER cost without insurance?
Without insurance, a 30-tablet supply of 100 mg extended-release tramadol can cost approximately $150. However, generic versions and discount programs can significantly reduce this cost[2][5].
What are the potential challenges facing the tramadol HCL ER market?
The market faces challenges such as potential side effects, regulatory concerns, and the need for careful monitoring of opioid use[4].
Are there any cost-reduction strategies available for tramadol HCL ER?
Yes, using generic versions, discount cards, and shopping around for lower prices can significantly reduce the cost of tramadol HCL ER[5].
Sources
- Stellar Market Research: Tramadol Market: Global Industry Analysis and Forecast (2024-2030)[1].
- Drugs.com: Ultram ER Prices, Coupons, Copay Cards & Patient Assistance[2].
- Global Market Insights: Tramadol Drug Market Size & Trends Analysis Report, 2032[3].
- Data Insights Market: Deep Dive into Tramadol Hydrochloride for Injection[4].
- SingleCare: How much is tramadol HCL (Qdolo) without insurance?[5].
More… ↓